News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Curis, Inc. (CRIS) Reports Cudc-907 Preliminary Data From THE Ongoing Phase 1 Trial AT American Society of Hematology 2013 Annual Meeting


12/10/2013 9:34:03 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LEXINGTON, Mass., Dec. 9, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel, targeted drug candidates for the treatment of human cancers, today announced preliminary first-in-human results from its ongoing Phase 1 trial of CUDC-907. These data will be presented today at the 55th Annual Meeting of the American Society of Hematology (ASH) in New Orleans, LA. Intermittent oral dosing of CUDC-907 appears to be better tolerated than continuous daily dosing (QD), which demonstrated preliminary evidence of anti-tumor activity with a partial response (PR) observed in 1 patient. In addition, stable disease (SD) has been observed in 7 of 11 response-evaluable patients. CUDC-907 is an oral, dual inhibitor of histone deacetylase (HDAC) and phosphoinositide 3-kinase (PI3K) enzymes that is currently under investigation in a Phase 1 trial in patients with relapsed/refractory lymphoma or multiple myeloma (MM).

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES